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Purpose of the study
TPV and DRV are ritonavir-boosted HIV protease inhibi-
tors (PI) indicated for use in TEPs with PI resistance. Both
agents have shown superior virologic and immunologic
responses in TEPs compared with first-generation PIs. In
the Utilization of HIV Drug Resistance in Treatment-Expe-
rienced Patients (UTILIZE) study, we assessed the pres-
ence of resistance to tipranavir, darunavir, and other
antiretroviral agents among HIV-1 isolates in treatment-
experienced patients.
Methods
UTILIZE was an observational study at 40 US sites that
examined clinician use of HIV drug-resistance testing in
TEPs failing a PI-based regimen. Patients were rand-
omized to have either a genotype (GT; Monogram Gen-
eSeq) or combined phenotype-genotype test (PGT;
Monogram Phenosense GT) to assist with treatment deci-
sion-making. For this analysis, only genotypic resistance
data were evaluated to assess PI cross-resistance.
Summary of results
246 patients enrolled and 236 had resistance testing, of
whom 139 (59%) had evidence of HIV-1 resistance to at
least one PI. Median HIV-RNA and CD4 count were
30,538 copies/mL and 197 cells/mm3, with no significant
differences between GT and PGT groups. Of the 139
patients with evidence of PI resistance, 28% of isolates
were resistant to all PIs; 58% and 55% remained sensitive
to TPV and DRV, respectively. In contrast, isolate suscepti-
bility to indinavir, lopinavir, atazanavir, saquinavir, or
nelfinavir was 21.6%, 20.1%, 19.4%, 16.5%, and 7.9%,
respectively. TPV-DRV discordance rates were similar:
15.1% TPV sensitive/DRV resistant and 12.2% TPV resist-
ant/DRV sensitive. 50% (7/14) of isolates from TEPs fail-
ing TPV remained sensitive to TPV, while 3% (1/29) of
isolates from TEPs failing DRV remained sensitive to DRV.
Conclusion
In this cohort of TEPs failing a PI-based regimen, 59% of
HIV-1 isolates demonstrated PI resistance. Of these iso-
lates, over 50% remained sensitive to either TPV or DRV,
with 27.3% sensitive to only one of the two drugs. In PI-
experienced patients, TPV and DRV remain the most likely
available PIs to use in constructing a new regimen.
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